Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 2/2007

01.02.2007 | Review

Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction

verfasst von: S. M. Lagarde, F. J. W. ten Kate, D. J. Richel, G. J. A. Offerhaus, J. J. B. van Lanschot

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

This review describes genetic and molecular changes related to adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) with emphasis on prognostic value and possibilities for targeted therapy in clinical setting.

Summary background data

Adenocarcinoma of the esophagus or GEJ is an aggressive disease with early lymphatic and hematogenous dissemination. Molecular pathology has revealed many molecular mechanisms of disease progression, which are related to prognosis. Some of these factors can be seen as prognostic factors per se. Better knowledge of molecular bases may lead to new paradigms, improved prognostication, early diagnosis and individually tailored therapeutic options.

Methods

A review of recent English literature (1990–October 2005) concerning esophageal adenocarcinoma was performed. This review focuses on genetic and molecular changes as prognosticators of adenocarcinoma of the esophagus and GEJ.

Results

A bewildering number of biomarkers have been described. Many genes and molecules have prognostic impact (cyclin D1, EGFR, Her-2/Neu, APC, TGF-β, Endoglin, CTGF, P53, Bcl-2, NF-κB, Cox-2, E-cadherin, β-catenin, uPA, MMP-1,3,7,9, TIMP, T h 1/T h 2 balance, CRP, PTHrP).

Conclusions

Adenocarcinomas of the esophagus and GEJ show multiple genetic alterations, which indicate that progression of cancer is a multistep complex process with many different alterations. Presumably, it is not one molecular factor that can predict the biological behavior of this cancer. The combination of diverse genetic alterations may better predict prognosis. In future, gene expression analysis with microarrays may reveal important prognostic information and the discovery of new genes and molecules associated with tumor progression and dissemination will enhance prognostication and offers adjuvant therapeutic options.
Literatur
1.
Bollschweiler E, Wolfgarten E, Gutschow C, et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92:549–55PubMed
2.
Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29:645–54PubMed
3.
Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049–53PubMed
4.
Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97:142–6PubMed
5.
van Blankenstein M., Looman CW, Hop WC, et al. The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett’s esophagus makes a difference. Am J Gastroenterol 2005; 100:766–74PubMed
6.
Siewert JR, Stein HJ, Feith M, et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001; 234:360–7PubMed
7.
Rudiger SJ, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232:353–61
8.
de Manzoni G., Pedrazzani C, Pasini F, et al. Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. Eur J Surg Oncol 2003; 29:506–10PubMed
9.
Hulscher JB, van Sandick JW, Tijssen JG, et al. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg 2000; 191:143–8PubMed
10.
Mariette C, Balon JM, Piessen G, et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97:1616–23PubMed
11.
Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg 2000; 87:1426–33PubMed
12.
Wayman J, Bennett MK, Raimes SA, et al. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 2002; 86:1223–9PubMed
13.
Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol 2003; 4:481–8PubMed
14.
Stein HJ, Siewert JR. Improved prognosis of resected esophageal cancer. World J Surg 2004; 28:520–5PubMed
15.
Hulscher JB, Tijssen JG, Obertop H, et al. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001; 72:306–13PubMed
16.
Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347:1662–9PubMed
17.
TNM: Classification of malignant tumours. New-York: Wiley-Liss, 2002
18.
American joint Committee on Cancer. AJCC cancer staging handbook. Philadelphia: Lippincott-Raven, 2002
19.
de Manzoni G., Pedrazzani C, Verlato G, et al. Comparison of old and new TNM systems for nodal staging in adenocarcinoma of the gastro-oesophageal junction. Br J Surg 2004; 91:296–303PubMed
20.
Eloubeidi MA, Desmond R, Arguedas MR, et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer 2002; 95:1434–43PubMed
21.
Lerut T, Coosemans W, Decker G, et al. Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg 2003; 126:1121–8PubMed
22.
Nigro JJ, Demeester SR, Hagen JA, et al. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg 1999; 117:960–8PubMed
23.
Lagarde SM, ten Kate FJ, de Boer DJ, et al. Extracapsular lymph node involvement in node-positive patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Am J Surg Pathol 2006; 30:171–6PubMed
24.
Yasui W, Oue N, Aung PP, et al. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005; 8:86–94PubMed
25.
Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/AKT pathways. Oncogene 2005; 24:7443–54PubMed
26.
Haber DA, Fearon ER. The promise of cancer genetics. Lancet 1998; 351(Suppl 2):SII1–8PubMed
27.
Kountouras J, Boura P, Lygidakis NJ. New concepts of molecular biology for colon carcinogenesis. Hepatogastroenterology 2000; 47:1291–7PubMed
28.
Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993; 7:139–46PubMed
29.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70PubMed
30.
Bergers G, Hanahan D, Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int J Dev Biol 1998; 42:995–1002PubMed
31.
Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464–8PubMed
32.
Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159–70PubMed
33.
Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104:510–3PubMed
34.
Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology 1995; 109:1541–6PubMed
35.
Barrett NR. Chronic peptic ulcer of the oesophagus and ‘oesophagitis’. Br J Surg 1950; 38:175–82PubMed
36.
Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett’s oesophagus. Lancet 2002; 360:1587–9PubMed
37.
Flejou JF. Barrett’s oesophagus: from metaplasia to dysplasia and cancer. Gut 2005; 54 (Suppl 1):i6–12PubMed
38.
Kyrgidis A, Kountouras J, Zavos C, et al. New molecular concepts of Barrett’s esophagus: clinical implications and biomarkers. J Surg Res 2005; 125:189–212PubMed
39.
Nair KS, Naidoo R, Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol 2005; 58:343–51PubMed
40.
Casson AG, Zheng Z, Evans SC, et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 2005; 104:730–739PubMed
41.
Miller CT, Moy JR, Lin L, et al. Gene amplification in esophageal adenocarcinomas and Barrett’s with high-grade dysplasia. Clin Cancer Res 2003; 9:4819–4825PubMed
42.
Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett’s esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000; 92:1316–1321PubMed
43.
Lin L, Prescott MS, Zhu Z, et al. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res 2000; 60:7021–7PubMed
44.
Sarbia M, Bektas N, Muller W, et al. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Cancer 1999; 86:2597–601PubMed
45.
Tenderenda M. A study on the prognostic value of cyclins D1 and E expression levels in resectable gastric cancer and on some correlations between cyclins expression, histoclinical parameters and selected protein products of cell-cycle regulatory genes. J Exp Clin Cancer Res 2005; 24:405–14PubMed
46.
Schwartz GK. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 2005; 23:4499–508PubMed
47.
Bible KC, Lensing JL, Nelson SA, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11:5935–41PubMed
48.
D’errico A, Barozzi C, Fiorentino M, et al. Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction. Br J Cancer 2000; 82:865–70PubMed
49.
Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett’s-associated neoplasia: correlation with prognosis. Mod Pathol 1997; 10:105–12PubMed
50.
Al-Kasspooles M, Moore JH, Orringer MB, et al. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993; 54:213–9PubMed
51.
Wilkinson NW, Black JD, Roukhadze E, et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004; 8:448–53PubMed
52.
Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19:554–68PubMed
53.
Wang SC, Hung MC. HER2 overexpression and cancer targeting. Semin Oncol 2001; 28:115–24PubMed
54.
Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999; 6:290–7PubMed
55.
Brien TP, Odze RD, Sheehan CE, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol 2000; 31:35–9PubMed
56.
Nakamura T, Nekarda H, Hoelscher AH, et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus. Cancer 1994; 73:1785–94PubMed
57.
Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist 2005; 10:590–601PubMed
58.
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673–84PubMed
59.
Safran H, Iannitti D, Ramanathan R, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004; 22:706–12PubMed
60.
Lam KY, Law SY, So MK, et al. Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma. Cancer 1996; 77:7–13PubMed
61.
Youssef EM, Matsuda T, Takada N, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 1995; 76:358–66PubMed
62.
Heeren PA, Kloppenberg FW, Hollema H, et al. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 2004; 24:2579–83PubMed
63.
Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett’s adenocarcinoma. Ann Surg 2001; 233:322–37PubMed
64.
Hardie LJ, Darnton SJ, Wallis YL, et al. p16 expression in Barrett’s esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 2005; 217:221–30PubMed
65.
Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene 2005; 24:4138–48PubMed
66.
Brock MV, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003; 9:2912–9PubMed
67.
Heeren PA, Kloppenberg FW, Hollema H, et al. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 2004; 24:2579–83PubMed
68.
Powell SM, Papadopoulos N, Kinzler KW, et al. APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology 1994; 107:1759–63PubMed
69.
Boynton RF, Blount PL, Yin J, et al. Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci USA 1992; 89:3385–8PubMed
70.
Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000; 92:1805–11PubMed
71.
Fukuchi M, Miyazaki T, Fukai Y, et al. Plasma level of transforming growth factor beta1 measured from the azygos vein predicts prognosis in patients with esophageal cancer. Clin Cancer Res 2004; 10:2738–41PubMed
72.
Saad RS, El-Gohary Y, Memari E, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 2005; 36:955–61PubMed
73.
Koliopanos A, Friess H, di Mola FF, et al. Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 2002; 26:420–7PubMed
74.
Iyer S, Wang ZG, Akhtari M, et al. Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther 2005; 4:261–6PubMedCrossRef
75.
Natsugoe S, Xiangming C, Matsumoto M, et al. Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 2002; 8:1838–42PubMed
76.
Kim YH, Lee HS, Lee HJ, et al. Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann Oncol 2004; 15:574–80PubMed
77.
Kim MA, Lee HS, Yang HK, et al. Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer 2005; 103:1439–46PubMed
78.
Casson AG, Tammemagi M, Eskandarian S, et al. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol 1998; 51:71–9PubMedCrossRef
79.
Ribeiro U, Jr., Finkelstein SD, Safatle-Ribeiro AV, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998; 83:7–18PubMed
80.
Ireland AP, Shibata DK, Chandrasoma P, et al. Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg 2000; 231:179–87PubMed
81.
Schneider PM, Stoeltzing O, Roth JA, et al. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett’s esophagus. Clin Cancer Res 2000; 6:3153–8PubMed
82.
Raouf AA, Evoy DA, Carton E, et al. Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus 2003; 16:17–23PubMed
83.
Garber K. Targeting mitochondria emerges as therapeutic strategy. J Natl Cancer Inst 2005; 97:1800–1PubMedCrossRef
84.
Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396:580–4PubMed
85.
Beardsmore DM, Verbeke CS, Davies CL, et al. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg 2003; 7:77–86PubMed
86.
bdel-Latif MM, O’Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004; 239:491–500
87.
Buskens CJ, van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122:1800–7PubMed
88.
Buskens CJ, Sivula A, van Rees BP, et al. Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut 2003; 52(12):1678–83PubMed
89.
Buskens CJ, Ristimaki A, Offerhaus GJ, et al. Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma. Scand J Gastroenterol Suppl 2003; 239:87–93PubMed
90.
Usselmann B, Newbold M, Morris AG, et al. Telomerase activity and patient survival after surgery for gastric and oesophageal cancer. Eur J Gastroenterol Hepatol 2001; 13:903–8PubMed
91.
Shammas MA, Koley H, Beer DG, et al. Growth arrest, apoptosis, and telomere shortening of Barrett’s-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology 2004; 126:1337–46PubMed
92.
Kelland LR. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics–current status and future prospects. Eur J Cancer 2005; 41:971–9PubMed
93.
Kleespies A, Guba M, Jauch KW, et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004; 87:95–104PubMed
94.
Mobius C, Stein HJ, Spiess C, et al. COX2 expression, angiogenesis, proliferation and survival in Barrett’s cancer. Eur J Surg Oncol 2005; 31:755–9PubMed
95.
von Rahden BH, Stein HJ, Puhringer F, et al. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005; 65:5038–44
96.
Mobius C, Stein HJ, Becker I, et al. Vascular endothelial growth factor expression and neovascularization in Barrett’s carcinoma. World J Surg 2004; 28:675–9PubMed
97.
Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie 2005; 28:281–8PubMed
98.
Nair KS, Naidoo R, Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol 2005; 58:343–51PubMed
99.
Krishnadath KK, Tilanus HW, van BM, et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997; 182:331–8PubMed
100.
Bottger TC, Youssef V, Dutkowski P, et al. Beta 1 integrin expression in adenocarcinoma of Barrett’s esophagus. Hepatogastroenterology 1999; 46:938–43PubMed
101.
Bottger TC, Youssef V, Dutkowski P, et al. Expression of CD44 variant proteins in adenocarcinoma of Barrett’s esophagus and its relation to prognosis. Cancer 1998; 83:1074–80PubMed
102.
Nekarda H, Schlegel P, Schmitt M, et al. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 1998; 4:1755–63PubMed
103.
Murray GI, Duncan ME, O’Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998; 185:256–61PubMed
104.
Tanioka Y, Yoshida T, Yagawa T, et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 2003; 89:2116–21PubMed
105.
Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett’s oesophageal adenocarcinoma. Br J Cancer 2001; 85:383–92PubMed
106.
Porte H, Triboulet JP, Kotelevets L, et al. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 1998; 4:1375–82PubMed
107.
Bramhall SR, Hallissey MT, Whiting J, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 86:1864–70PubMed
108.
Darnton SJ, Hardie LJ, Muc RS, et al. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int J Cancer 2005; 115:351–8PubMed
109.
Menke-Pluymers MB, Hop WC, Mulder AH, et al. DNA ploidy as a prognostic factor for patients with an adenocarcinoma in Barrett’s esophagus. Hepatogastroenterology 1995; 42:786–8PubMed
110.
Nakamura T, Nekarda H, Hoelscher AH, et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett’s esophagus. Cancer 1994; 73:1785–94PubMed
111.
Bottger T, Dutkowski P, Kirkpatrick CJ, et al. Prognostic significance of tumor ploidy and histomorphological parameters in adenocarcinoma of Barrett’s esophagus. Dig Surg 1999; 16:180–5PubMed
112.
Wu TT, Watanabe T, Heitmiller R, et al. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998; 153:287–94PubMed
113.
van Sandick JW, Boermeester MA, Gisbertz SS, et al. Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome. Cancer Immunol Immunother 2003; 52:617–24PubMed
114.
Romano F, Cesana G, Berselli M, et al. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients. J Surg Oncol 2004; 88:240–7PubMed
115.
Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005; 18:146–50PubMed
116.
Deans C, Wigmore S, Paterson-Brown S, et al. Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer 2005; 103:1810–8PubMed
117.
Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004; 23:7274–82PubMed
118.
Rizvi AZ, Hunter JG, Wong MH. Gut-derived stem cells. Surgery 2005; 137:585–90PubMed
119.
Jonsson M, Dejmek J, Bendahl PO, et al. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 2002; 62:409–16PubMed
120.
Dejmek J, Dejmek A, Safholm A, et al. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 2005; 65:9142–6PubMed
121.
Kremenevskaja N, von WR, Rao AS, et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 2005; 24:2144–54
122.
Watkins DN, Peacock CD. Hedgehog signalling in foregut malignancy. Biochem Pharmacol 2004; 68:1055–60PubMed
123.
Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003; 425:846–51PubMed
124.
Katoh M, Katoh M. Notch ligand, JAG1, is evolutionarily conserved target of canonical WNT signaling pathway in progenitor cells. Int J Mol Med 2006; 17:681–5PubMed
125.
Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005; 65:8530–7PubMed
126.
Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005; 24:7443–54PubMed
127.
Chambers AF, Groom AC, Macdonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2:563–72PubMed
128.
Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118:277–9PubMed
129.
van’t Veer L, Dai H, Van de Vijver M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530–6
130.
Xu Y, Selaru FM, Yin J, et al. Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett’s esophagus and esophageal cancer. Cancer Res 2002; 62:3493–7PubMed
131.
Kimchi ET, Posner MC, Park JO, et al. Progression of Barrett’s metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res 2005; 65:3146–54PubMed
132.
Brabender J, Marjoram P, Salonga D, et al. A multigene expression panel for the molecular diagnosis of Barrett’s esophagus and Barrett’s adenocarcinoma of the esophagus. Oncogene 2004; 23:4780–8PubMed
Metadaten
Titel
Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction
verfasst von
S. M. Lagarde
F. J. W. ten Kate
D. J. Richel
G. J. A. Offerhaus
J. J. B. van Lanschot
Publikationsdatum
01.02.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9262-y

Weitere Artikel der Ausgabe 2/2007

Annals of Surgical Oncology 2/2007 Zur Ausgabe

OriginalPaper

Biomarkers Predict Outcomes Following Cytoreductive Surgery for Hepatic Metastases from Functional Carcinoid Tumors

OriginalPaper

Surgical Treatment of Solitary Thyroid Nodules Via Fine-Needle Aspiration Biopsy and Frozen-Section Analysis

OriginalPaper

A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease

OriginalPaper

Prognostic Significance of Immunohistochemically Detected Blood and Lymphatic Vessel Invasion in Colorectal Carcinoma: Its Impact on Prognosis

OriginalPaper

Lymphoseek: A Molecular Imaging Agent for Melanoma Sentinel Lymph Node Mapping

OriginalPaper

Cancer Cells Cause Vascular Endothelial Cell (vEC) Retraction via 12(S)HETE Secretion; The Possible Role of Cancer Cell Derived Microparticle

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise